Join Andelyn’s Newsletter

Your Source for Quality Insights on Cell and Gene Therapies

We are committed to advancing the future of cell and gene therapies. By subscribing to our newsletter, you’ll receive:

icon for expert perspectives
Expert perspectives on the latest industry developments
icon for educational content
Educational content on therapies from concept to commercialization
icon for exclusive insights
Exclusive insights into our pioneering work in rare diseases
icon for industry conferences
Updates on conference attendance and technical presentations

News & Press Releases

Press Release

September 18, 2026

Andelyn Biosciences and its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following the FDA’s Approval of Ultragenyx’s Fayuvi™ for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)Andelyn Biosciences and its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following the FDA’s Approval of Ultragenyx’s Fayuvi™ for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
Press Release

September 1, 2026

Andelyn Biosciences to Scale Manufacturing for Genprex’s Diabetes Gene Therapy ProgramAndelyn Biosciences to Scale Manufacturing for Genprex’s Diabetes Gene Therapy Program
News

August 22, 2026

The Columbus Dispatch | Fore One Purpose returns to help family battling rare diseaseThe Columbus Dispatch | Fore One Purpose returns to help family battling rare disease
News

August 19, 2026

Bioprocess Insider | Andelyn partners with Queen’s University on gene therapy for GM2 gangliosidosesBioprocess Insider | Andelyn partners with Queen’s University on gene therapy for GM2 gangliosidoses
View All News & Press Releases
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
PreferencesDenyAccept